BioMarin Pharmaceutical Inc. is financing its $2 billion acquisition of Amicus Therapeutics, complemented by a new $850 million offering of senior unsecured notes.

Information on the Target

BioMarin Pharmaceutical Inc. is a prominent biotechnology company headquartered in San Rafael, California, that specializes in developing innovative therapies for rare genetic diseases. Established in 1997, BioMarin has built a successful portfolio that includes eight commercial products and a robust pipeline of clinical and preclinical candidates. The company is renowned for its commitment to leveraging genetic science to create transformative medicines aimed at improving patient outcomes.

As part of its strategic growth initiatives, BioMarin is acquiring Amicus Therapeutics, Inc., a company that focuses on therapies for people living with rare metabolic diseases. This acquisition is expected to enhance BioMarin's capabilities and therapeutic offerings in the rare disease sector through Amicus' innovative portfolio and research expertise.

Industry Overview in the Target’s Specific Country

The biotechnology industry in the United States is one of the most advanced and dynamic sectors globally, characterized by rapid innovation and substantial investments in research and development. The U.S. is home to numerous